The role of deubiquitinating enzymes in cancer drug resistance Parthasaradhireddy TanguturiKye-Seong KimSuresh Ramakrishna Review Article 07 March 2020 Pages: 627 - 639
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma Michele ReniUmberto PerettiLuca Gianni Original Article 10 March 2020 Pages: 641 - 650
Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer Jiyoung KeumHee Seung LeeSeungmin Bang Original Article 17 March 2020 Pages: 651 - 659
Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination Xiaojun LiuYingjun JiangWilliam Plunkett Original Article 18 February 2020 Pages: 661 - 672
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors Anthony W. TolcherRazelle KurzrockLi Yan Original Article 15 February 2020 Pages: 673 - 683
Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer Soo Jin KimKyung Hwan JegalKeon Wook Kang Original Article 11 March 2020 Pages: 685 - 697
A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor-ÎşB activation Ke LiYun ZhouJimin Liang Original Article 17 March 2020 Pages: 699 - 709
Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic–pharmacodynamic model in gastrointestinal cancer patients Usman ArshadSu-arpa PloylearmsaengMax Taubert Original Article Open access 09 March 2020 Pages: 711 - 722
Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma Qiuying ChenBin ZhangShuixing Zhang Original Article 02 March 2020 Pages: 723 - 730
Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: in vitro and in vivo evaluation Min LiJianying PeiShuzhang Du Original Article 07 March 2020 Pages: 731 - 739
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up Bhavana PothuriAllison L. BrodskyFranco Muggia Original Article 13 February 2020 Pages: 741 - 751
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients Guillemette E. BenoistInge M. van OortNielka P. van Erp Original Article Open access 19 February 2020 Pages: 753 - 760
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer Ou YamaguchiHisao ImaiKyoichi Kaira Original Article 19 March 2020 Pages: 761 - 771
Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia Hiroaki GotoYuki YoshinoShoko Goto Original Article 06 March 2020 Pages: 773 - 783
SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome Xin LiaoLiu HuangXianglin Yuan Original Article 19 March 2020 Pages: 785 - 792
The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats Bronwen J. MayoKate R. SecombeJoanne M. Bowen Original Article 14 February 2020 Pages: 793 - 803
Metabolism and pharmacokinetics characterization of metarrestin in multiple species Elias C. PadilhaPranav ShahXin Xu Original Article 17 March 2020 Pages: 805 - 816
Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation Aurélie LombardHitesh MistryKayode Ogungbenro Original Article Open access 13 March 2020 Pages: 817 - 825
Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma Louis T. RodgersCynthia M. Lester McCullyKatherine E. Warren Short Communication 01 January 2020 Pages: 827 - 830